SMSimon Messing

Simon Messing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Messing has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TwinStrep™ tag purification leads to differences in RAF1 RAS binding domain and cysteine-rich domain conformation

    by Gabriel Cornilescu, Shelley Perkins, Vanessa E. Wall, Robert A. D'IPpolito, Troy Taylor, Matthew Drew, Peter H. Frank, Min Hong, Kelly Snead, Monalisa Swain, et al.

  • Molecular mechanism of KRAS binding to BRAF and its regulation by the BRAF-specific region

    by Daniel A. Bonsor, Suzanne I. Sandin Lawrence, Timothy H. Tran, Monalisa Swain, Srisathiyanarayanan Dharmaiah, Jennifer Mehalko, Simon A. Messing, Dwight V. Nissley, Frank McCormick, Andrew G. Stephen, et al.

  • Open Access

    Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS

    by Matthew J. Whitley, Marcin Dyba, Mayukh Chakrabarti, Brian P. Smith, Albert H. Chan, John-Paul Denson, Simon A. Messing, Ken Lin, Gabriel Cornilescu, Trent E. Balius, et al.

    Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and cellular approaches. Covalent and noncovalent binding measurements reveal mutation- and inhibitor-specific reductions in drug engagement across inhibitor classes. Structural analyses identify two principal resistance mechanisms: Type I, involving loss of key inhibitor contacts, and Type II, involving stabilization of pocket-occluding Switch-II conformations. Y96D exhibits both mechanisms through nucleotide-dependent non-native intramolecular interactions, whereas R68S primarily exhibits Type I resistance with modest Type II effects on pocket architecture and Switch-region dynamics. Y96C, H95Q and Q99L predominantly exhibit Type I resistance. All mutants retain RAF1 binding, whereas PI3Kα binding is selectively reduced by R68S and Q99L. Together, these findings provide structural insights for understanding on-target resistance to Switch-II pocket inhibitors.

  • High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study

    by Shelley Perkins, Sophie Krahnke, Erik K. Larsen, Matthew Drew, Peter H. Frank, Min Hong, Dana Rabara, Vanessa E. Wall, Carissa Grose, William Gillette, et al.


  • Open Access

    Disulfide tethering reveals cryptic pockets in oncogenic KRAS

    by Trent E. Balius, Marcin Dyba, Vandana Kumari, John-Paul Denson, Ming Yi, Alok K. Sharma, Priyanka Prakash, Emily Alberico, Simon Messing, Vanessa Wall, et al.

    Disulfide tethering is a site-directed method of drug discovery used to identify hits for challenging targets. We applied tethering to target oncogenic KRAS, a small GTPase once considered undruggable due to its high nucleotide affinity and a perceived absence of binding sites. We prepared a library of 2160 disulfide-containing fragments. We screened over 1000 compounds against a panel of 83 engineered cysteine mutants of KRAS G12D in the active conformation and screened the full library for a subset of 30 mutants. For select mutants and hits, we performed 2-mercaptoethanol competition assays (βME-50) to prioritize ligands. Ligandability analysis comparing hit rates across mutant residues enabled the identification of druggable hot spots. Our studies confirmed known binding sites, including the Switch-II / α-helix 3 pocket. In addition, we identified previously undescribed cryptic pockets and validated select hits using computational chemistry and NMR spectroscopy. These pockets represent promising opportunities for future drug discovery campaigns.


  • Structural basis for LZTR1 recognition of RAS GTPases for degradation

    by Srisathiyanarayanan Dharmaiah, Daniel A. Bonsor, Stephanie P. Mo, Alvaro Fernandez-Cabrera, Albert H. Chan, Simon Messing, Matthew Drew, Martha Vega, Dwight V. Nissley, Dominic Esposito, et al.

    The RAS family of small guanosine triphosphatases (GTPases) are tightly regulated signaling molecules that are further modulated by ubiquitination and proteolysis. Leucine Zipper-like Transcription Regulator 1 (LZTR1), a substrate adapter of the Cullin-3 RING E3 ubiquitin ligase, binds specific RAS GTPases and promotes their ubiquitination and proteasomal degradation. We present structures of LZTR1 Kelch domains bound to RIT1, MRAS, and KRAS, revealing interfaces that govern RAS isoform selectivity and nucleotide specificity. Biochemical and structural analyses of disease-associated Kelch domain mutations revealed three types of alterations: impaired substrate interaction, loop destabilization, and blade-blade repulsion. In cellular and mouse models, mutations disrupting substrate binding phenocopied LZTR1 loss, underscoring its substrate specificity. These findings define RAS recognition mechanisms by LZTR1 and suggest a molecular glue strategy to degrade oncogenic KRAS.


  • Open Access

    Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine

    by Anna E. Maciag, Yue Yang, Alok K. Sharma, David M. Turner, Caroline J. DeHart, Hazem Abdelkarim, Lixin Fan, Brian P. Smith, Vandana Kumari, Marcin Dyba, et al.

    RAS is the most frequently mutated oncogene in cancer. RAS proteins show high sequence similarities in their G-domains but are significantly different in their C-terminal hypervariable regions (HVR). These regions interact with the cell membrane via lipid anchors that result from posttranslational modifications (PTM) of cysteine residues. KRAS4b is unique as it has only one cysteine that undergoes PTM, C185. Small molecule covalent modification of C185 would block any form of prenylation and subsequently inhibit attachment of KRAS4b to the cell membrane, blocking its biological activity. We translated this concept to the discovery and development of disulfide tethering screen hits into irreversible covalent modifiers of C185. These compounds inhibited proliferation of KRAS4b-driven mouse embryonic fibroblasts, but not cells driven by N-myristoylated KRAS4b that harbor a C185S mutation and are not dependent on C185 prenylation. Top–down proteomics was used to confirm target engagement in cells. These compounds bind in a pocket formed when the HVR folds back between helix 3 and 4 in the G-domain (HVR-α3-α4). This interaction can happen in the absence of small molecules as predicted by molecular dynamics simulations and is stabilized in the presence of C185 binders as confirmed by small-angle X-ray scattering and solution NMR. NOESY-HSQC, an NMR approach that measures internuclear distances of 6 Å or less, and structure analysis identified the critical residues and interactions that define the HVR-α3-α4 pocket. Further development of compounds that bind to this pocket could be the basis of a new approach to targeting KRAS cancers.


  • Top Cited Papers
    Open Access

    Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation

    by Daniel Czyzyk, Wupeng Yan, Simon Messing, William Gillette, Takashi Tsuji, Mitsuhiro Yamaguchi, Shinji Furuzono, David M. Turner, Dominic Esposito, Dwight V. Nissley, et al.

    Mutations in RAS and PI3Kα are major drivers of human cancer. Their interaction plays a crucial role in activating PI3Kα and amplifying the PI3K-AKT-mTOR pathway. Disrupting RAS-PI3Kα interaction enhances survival in lung and skin cancer models and reduces tumor growth and angiogenesis, although the structural details of this interaction remain unclear. Here, we present structures of KRAS, RRAS2, and MRAS bound to the catalytic subunit (p110α) of PI3Kα, elucidating the interaction interfaces and local conformational changes upon complex formation. Structural and mutational analyses highlighted key residues in RAS and PI3Kα impacting binding affinity and revealed isoform-specific differences at the interaction interface in RAS and PI3K isoforms, providing a rationale for their differential affinities. Notably, in the RAS-p110α complex structures, RAS interaction with p110α is limited to the RAS-binding domain and does not involve the kinase domain. This study underscores the pivotal role of the RAS-PI3Kα interaction in PI3Kα activation and provides a blueprint for designing PI3Kα isoform-specific inhibitors to disrupt this interaction.


  • Improvements in large-scale production of tobacco etch virus protease

    by Simon Messing, Kirsten Barnhart, Matthew Drew, Natalie Granato-Guerrero, Carissa Grose, Brianna Higgins, Min Hong, Jenna Hull, Shelley Perkins, Ivy Poon, et al.


  • Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase

    by Simon Messing, Stephanie R.T. Widmeyer, John-Paul Denson, Jennifer Mehalko, Vanessa E. Wall, Matthew Drew, Kelly Snead, Min Hong, Carissa Grose, Dominic Esposito, et al.